The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen levels.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
151
Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
MRCCC Siloam Hospital Semanggi
Jakarta, DKI Jakarta, Indonesia
Effects of genotype and phenotype of CYP2D6 on plasma and serum concentration of tamoxifen and its metabolites
Time frame: 8 weeks after initial tamoxifen intake
Effects of dose recommendation of tamoxifen based on CYP2D6 genotyping results on endoxifen levels
Time frame: 8 weeks after dose recommendation
Frequencies of CYP2D6 alleles in female Indonesian population
Time frame: Baseline, pre-intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.